Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net
Open Access
- 10 December 2014
- Vol. 349 (dec10 5) , g7518
- https://doi.org/10.1136/bmj.g7518
Abstract
Randomised controlled trials (RCTs) offer the fastest and most rigorous assessment of vaccine efficacy.1 But they are ethical only if there is “clinical equipoise”—genuine uncertainty in the medical community about whether the experimental intervention will do more good than harm.2 We argue that Ebola virus vaccine RCTs can achieve clinical equipoise without sacrificing scientific rigour by providing trial participants who develop Ebola virus disease (EVD) with enhanced supportive care and access to experimental therapeutics. Most discussions have analysed Ebola vaccine and treatment …Keywords
This publication has 7 references indexed in Scilit:
- Clinical Presentation of Patients with Ebola Virus Disease in Conakry, GuineaNew England Journal of Medicine, 2015
- Clinical Illness and Outcomes in Patients with Ebola in Sierra LeoneNew England Journal of Medicine, 2014
- Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward ProjectionsNew England Journal of Medicine, 2014
- Randomised controlled trials for Ebola: practical and ethical issuesThe Lancet, 2014
- Ebola: an opportunity for a clinical trial?BMJ, 2014
- Equipoise should be amended, not abandonedClinical Trials, 2011
- The Ethics of Clinical Research in the Third WorldNew England Journal of Medicine, 1997